Tamburi Investment Partners S.p.A. (0G9J)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 8.840 |
|---|---|
| 52-week range | 7.560 – 10.260 |
| Return, 1 month / 3 months | −0.9% / −5.9% |
| Return, 1 year / 3 years | +7.3% / +19.0% |
| Trend | Below its 200-day average |
| RSI (14) | 47 |
| Volatility (1 year) | 28.1% |
| Worst drawdown (1 year) | -25.2% |
| Average daily value traded | 0.10M EUR |
| Dividend yield | 2.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Tamburi Investment Partners is an Italian investment holding company based in Milan. It takes significant minority stakes in established companies, mostly in Italy and elsewhere in Europe, and supports their development over the long term. Its portfolio spans industrial, consumer and service businesses, and it often works alongside founding families and managers. The company also holds interests in investment vehicles that pursue similar stakes in mid-sized firms.
The shares are listed on the London Exchange in UK under the code 0G9J, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Tamburi Investment Partners S.p.A. (0G9J) trades on the London Exchange in UK. It last closed at EUR 8.840 on 22 October 2026.
Its price-based Market X-Ray is 50 out of 100 (a fair price profile), ranking 2,022 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 7.3% and over the last three months it fell 5.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 55 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -1.3% | ||
| From 52-week high | -13.5% | ||
| Momentum | 53 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -5.9% | ||
| 6-month return | 7.8% | ||
| 12-month return, skipping the last month | 8.3% | ||
| Stability (higher is calmer) | 63 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.2% | ||
| Liquidity | 21 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.10M EUR | ||
| Zero-volume days | 31.7% | ||
| Income | 45 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.9% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | −2.4% |
|---|---|
| 1 month | −0.9% |
| 3 months | −5.9% |
| 6 months | +7.8% |
| 1 year | +7.3% |
| 3 years | +19.0% |
| 5 years | −3.0% |
Signals
| 50-day / 200-day average | 9.190 / 8.954 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.267 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 Jun 2026 | EUR 0.2600 |
| 23 Jun 2025 | EUR 0.1600 |
| 24 Jun 2024 | EUR 0.1500 |
| 19 Jun 2023 | EUR 0.1300 |
| 23 May 2022 | EUR 0.1100 |
| 24 May 2021 | EUR 0.1000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.